CRNX Stock Summary and Trading Ideas (Crinetics Pharmaceuticals | NASDAQ:CRNX)

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

What symbol and exchange does Crinetics Pharmaceuticals shares trade?

Crinetics Pharmaceuticals trades on the NASDAQ stock market under the symbol CRNX.

What is Crinetics Pharmaceuticals stock price doing today?

As of July 31, 2026, CRNX stock price declined to $83.52 with 1,741,915 million shares trading.

What is Crinetics Pharmaceuticals's Beta?

CRNX has a beta of 1.59, meaning it tends to be more sensitive to market movements. CRNX has a correlation of 0.05 to the broad based SPY ETF.

How much is Crinetics Pharmaceuticals worth?

CRNX has a market cap of $8.84 billion. This is considered a Mid Cap stock.

How much money does Crinetics Pharmaceuticals make?

Last quarter Crinetics Pharmaceuticals reported $10 million in Revenue and -$1.23 earnings per share. This beat revenue expectation by $2 million and met earnings estimates .

What is the highest and lowest price Crinetics Pharmaceuticals traded in the last 3 year period?

In the last 3 years, CRNX traded as high as $84.00 and as low as $15.76.

What are the top ETFs holding Crinetics Pharmaceuticals?

The top ETF exchange traded funds that CRNX belongs to (by Net Assets): IWM, VTI, VB, IWO, IBB.

Is Crinetics Pharmaceuticals (CRNX) a good investment?

CRNX has outperformed the market in the last year with a return of +192.1%, while the SPY ETF gained +19.4%. In the last 3 month period, CRNX beat the market returning +115.4%, while SPY returned +4.2%. However, in the most recent 2 weeks CRNX has underperformed the stock market by returning -0.4%, while SPY returned +0.5%.

What are the support and resistance levels for Crinetics Pharmaceuticals (CRNX)?

CRNX support price is $81.60 and resistance is $85.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRNX shares will trade within this expected range on the day.